Doing our part in Canada's push towards self reliance in the fight against COVID-19
Vaccigen ltd is a Canadian company created to bring in all the technical and manufacturing capabilities of Ocugen Inc. from the USA to Canada. Ocugen is a global leader in Gene Therapies, Biotechnology, Vaccine research and production.
Publications
Phase 3 Results for COVAXIN Vaccine are available
Novel vaccine adjuvant used in COVAXIN was developed by National Institute of Health, USA
COVAXIN effectiveness on B.1.617 Delta variant
10,00,039
In 12 Countries
In 12 Countries
About Us
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases aswell as co-developing and manufacturing various vaccines. Ocugen’s Covaxin Covid-19 vaccine co-development partner, Bharat Biotech, shares phase 3, second interim results demonstrating 100% protection against severe disease including hospitalization and overall clinical efficacy of 78%. Covaxin is already given to millions of people in India and around the world.
Learn How Different Types of Covid 19 Vaccines Work
Vaccine Overview
Our vaccine works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus.
Key Findings: Phase 3 Clinical Trial Involving 25,800 subjects
- Protective Effect 78% All Disease
- 65% Delta Variant*
- AE Profile 12% Adverse Events**
- 93% Severe Disease
- < 0.5% Serious Adverse Events**
*Post hoc analysis ** Placebo group
| Protective Effect | 78%All Disease | 65%Delta Variant* | 93%Severe Disease |
|---|---|---|---|
| AE Profile | 12%Adverse Events** | 0.5%Serious Adverse Events** | *Post hoc analysis |
Vaccine Overview
Our vaccine works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus.
Key Findings: Phase 3 Clinical Trial Involving 25,800 subjects
Protective Effect
78% All Disease
65% Delta Variant
93% Severe Disease
AE Profile
12% Adverse Events**
<0.5% Serious Adverse Events**
*Post hoc analysis
**Placebo group
- Protective Effect 78% All Disease
- 65% Delta Variant*
- 93% Severe Disease
- AE Profile 12% Adverse Events**
- < 0.5% Serious Adverse Events**
*Post hoc analysis ** Placebo group
Scientific Advisory Board
Scientific Advisory Board
Pipeline Overview
Pipeline Overview
Cantor Fireside Chat with Ocugen (OCGN)
Cantor Fireside Chat with Ocugen (OCGN)
Publications
Preclinical Product Development
Animal Challenge Studies – Hamsters
Animal Challenge Studies – Rhesus Macaques
Human Clinical Trials – Phase I
Human Clinical Trials – Phase II
Covaxin Efficacy
Neutralization of B.1.1.28 P2 variant
Inactivated COVID-19 vaccine BBV152
Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variants
Ocugen Announces Positive Top-Line Data For COVID-19
Ocugen Announces FDA Approval For Enrollment of Pediatric Patients
Ocugen Announes Positive Preliminary safety and Efficacy Results
Disclaimer
Covaxin (BBV152) is an investigational whole-virus inactivated COVID-19 vaccine candidate, not yet approved in Canada. These links reflect published research conducted on the candidate vaccine.
Copy Rights @ 2021.
Copyright @ 2021.